Abstract
Currently, the standard first-line treatment for patients with HER2 overexpression in metastatic breast cancer is trastuzumab in combination with taxane. Where progress of the disease is seen with trastuzumab, lapatinib in combination with capecitabine, or changing to treatment using trastuzumab with capecitabine has demonstrated interesting results. With the aim of further improving results for these patients, a number of new therapies are being evaluated. Combining trastuzumab with other monoclonal antibodies such as pertuzumab and bevacizumab, or with cytotoxins like TDM1, or with anti-mTORs such as everolimus, which targets other signalling pathways used in cell proliferation and survival, has shown promising results and will soon be part of our range of therapies.
Résumé
Les patientes atteintes d’un cancer du sein métastatique surexprimant HER2 bénéficient aujourd’hui d’un traitement standard par trastuzumab associé à un taxane en première ligne. En cas de progression sous trastuzumab, le lapatinib en association avec la capécitabine ou la poursuite du traitement par trastuzumab avec la capécitabine a démontré son intérêt. Dans le but d’améliorer encore les résultats dans cette population, nombre de nouvelles thérapies sont en cours d’évaluation. Des associations combinant le trastuzumab avec d’autres anticorps monoclonaux comme le pertuzumab et le bevacizumab ou avec un cytotoxique comme le TDM1, ou des antimTOR comme l’éverolimus qui ciblent d’autres voies de signalisation impliquées dans la prolifération et la survie cellulaires sont prometteuses et vont enrichir bientôt notre arsenal thérapeutique.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Références
Baselga J, Gelmon KA, Verma S, et al. (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138–1144
Baselga J, Cortés J, Kim SB, et al. for the CLEOPATRA Study Group (2011) Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. N Engl J Med (article publié le 7 décembre 2011: NEJM.org)
Blackwell KL, Burstein HJ, Storniolo AM, et al. (2010) Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124–1130
Cameron D, Casey M, Press M, et al (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 112: 533–543
Dawood S, Broglio K, Buzdar AU, et al. (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28: 92–98
Gasparini G, Gion M, Mariani L, et al (2007) Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with HER2 positive advanced breast cancer. Breast Cancer Res Treat 101: 355–365
Geyer CE, Forster J, Lindquist D, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733–2743
Gianni L, Llado A, Bianchi G, et al (2010) Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 1131–1137
Johnston S, Pippen J Jr, Pivot X, et al. (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27: 5538–5546
Kaufman B, Mackey JR, Clemens MR, et al (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529–5537
Marty M, Cognetti F, Maraninchi D, et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274
Slamon DJ, Leyland-Jones B, Shak S, et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792
Soria JC, Blay JY, Spano JP, et al. (2011) Added value of molecular targeted agents in oncology. Ann Oncol 22(8): 1703–1716. Epub 2011 Feb 7
von Minckwitz G, du Bois A, Schmidt M, et al (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J Clin Oncol 27: 1999–2006
Wardley AM, Pivot X, Morales-Vasquez F, et al. (2010) Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28: 976–983
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Pivot, X., Jary, M., Dobi, E. et al. Cancer du sein métastatique surexprimant HER2 : évolutions des thérapeutiques. Oncologie 14, 37–40 (2012). https://doi.org/10.1007/s10269-011-2106-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-011-2106-9